Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.14726 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infantile Bullous Pemphigoid: Vaccination and SARS-CoV-2 Infection as Triggers.
Cureus
August 2024
Dermatology, Cliniques Universitaires Saint-Luc, Brussels, BEL.
Bullous pemphigoid (BP) is an acquired auto-immune blistering disease, which is uncommon during childhood. Infantile BP usually has a good prognosis with rare recurrence and the suspected triggers are vaccines or viruses. We report the case of a three-month-old infant girl who presented with BP a week after a SARS-CoV-2 infection and three weeks after the first doses of polio, tetanus, diphtheria, pertussis, Haemophilus influenzae type-b, hepatitis, and pneumococcus vaccinations.
View Article and Find Full Text PDFSuccessful treatment of infantile refractory bullous pemphigoid with baricitinib.
Australas J Dermatol
December 2024
Dermatology Center, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Infantile bullous pemphigoid (BP) is a rare autoantibody-mediated skin disorder. We report the effective treatment of a 6-month-old infant with BP using baricitinib, a Janus kinase (JAK) inhibitor, after failure with steroids and intravenous immunoglobulin. The patient achieved full remission and discontinued all medications without any relapses.
View Article and Find Full Text PDFInfantile Bullous Pemphigoid: A Case Report.
Clin Cosmet Investig Dermatol
July 2024
Pathology Department, Imam Abdulrahman Bin Faisal University, King Fahad University Hospital, Khobar, Saudi Arabia.
Article Synopsis
- Infantile bullous pemphigoid (IBP) is a rare autoimmune skin disorder in infants that causes blisters and other skin issues, leading to discomfort and potential complications.
- A clinical case of a 4-month-old boy with generalized tense bullae highlighted the unique signs of IBP and confirmed the diagnosis through pathological examination.
- The study emphasizes the importance of early diagnosis and tailored treatment strategies to effectively manage IBP and improve outcomes for affected infants.
Effect of clarithromycin in a case of infantile bullous pemphigoid.
Pediatr Dermatol
March 2024
Department of Dermatology, Mediclinic Middle East, Dubai, United Arab Emirates.
Although rare, cases of infantile or childhood bullous pemphigoid are increasingly being reported in the literature. Treatment challenges, which are amplified in infancy, necessitate balancing efficacy and avoiding long-term risks. In this report, clarithromycin was successfully used to establish and maintain disease remission, offering insights into its immunomodulatory effects, making it a compelling steroid-sparing choice with a favorable side effect profile.
View Article and Find Full Text PDFA Case of Bullous Pemphigoid in a Five-Month-Old Female: A Rare Presentation.
Cureus
August 2023
Dermatology, Dubai Academic Health Corporation, Dubai, ARE.
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, characterized by the presence of tense bullae and erosions of the skin and rarely at the mucous membranes. It often presents in the elderly population, but the incidence is rare in children and infants, with few reported cases in this population in the literature. We report a rare presentation of bullous pemphigoid in a five-month-old girl who presented to our clinic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!